Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

This analysis found alirocumab was associated with a reduction in incidence of MACE in patients with eGFR ≥90 mL/min/1.73m2 (HR 0.78, 95% CI 0.67–0.92; P = 0.003) and 60 to <90 (0.83, 0.73–0.95; P = 0.006), but not in those with eGFR < 60 (n=0.97, 0.81–1.18; P = 0.784).

European Heart Journal